Remnant Cholesterol and Fenofibrate-Statin Therapy Evidence Summary

Vikrama Raja published a dataset on fenofibrate-statin therapy for managing remnant cholesterol on figshare in June 2026. The 24.3 KB Excel file synthesizes evidence on triglyceride-rich lipoproteins and residual cardiovascular risk. The description references clinical trial and real-world study data spanning up to two decades.

Use Cases

• Reviewing evidence on remnant cholesterol as a cardiovascular risk factor based on the description's focus.
• Analyzing the role of fenofibrate-statin combination therapy based on the described clinical and real-world studies.
• Studying long-term safety data for fenofibrate based on the mention of studies spanning up to two decades.

Strengths

• The dataset description references evidence from clinical trials and real-world studies.
• The description cites long-term safety data spanning up to two decades.

Limitations

• The dataset is very small at 24.3 KB, indicating limited scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

Vikrama Raja via figshare

Freshness

Last updated 2026-06-04 04:27:22; freshness should be verified.